Is Mounjaro or Ozempic Better for Losing Weight? (October 2026)

01 · The verdict

Which is better for losing weight: Mounjaro or Ozempic?

For weight loss, the real comparison is Mounjaro against Wegovy. Tirzepatide averaged more weight loss than semaglutide 2.4mg in the direct comparison, SURMOUNT-5, and Ozempic is not a UK weight-loss medicine at all.¹⁵ That does not make Wegovy a poor treatment. Both are effective, licensed options, and the right one depends on your health profile, tolerance and prescriber advice rather than the headline number alone.¹⁵

Mounjaro may suit adults whose prescriber recommends a once-weekly pen that is stepped up over time. Wegovy (semaglutide 2.4mg) may suit people whose prescriber prefers a single-action GLP-1 medicine, or who have a history that points that way. Ozempic is for type 2 diabetes. A regulated UK pharmacy will not supply it for weight loss.¹⁸

If you came here comparing the two for diabetes control, see our guide on Ozempic or Mounjaro for type 2 diabetes. For the reasoning behind the weight-loss gap, read why Mounjaro outperforms Ozempic.

02 · Side by side

Mounjaro vs Ozempic vs Wegovy at a glance

The Mounjaro and Wegovy results come from the same trial, so that one comparison is fair. Do not line up figures from other trials as if they were head to head. Prices for the Mounjaro pen and the Wegovy pen are live on their product pages.

03 · Deciding

The factors that should decide it

Five factors matter most when choosing between these medicines. The first is licensing: Ozempic is licensed for type 2 diabetes only, so for weight loss the real comparison is Mounjaro against Wegovy.¹⁸ The second is the size of average effect. SURMOUNT-5 favours tirzepatide, and the gap is not small.¹⁵

The third is tolerance. Gastrointestinal side effects are common with this class, and your own history matters more than a trial average. Our guide on whether Mounjaro is better tolerated than Ozempic covers this further. The fourth is cost. Mounjaro's standard price is £169.99 for the 2.5mg pen, and our comparison of Mounjaro and Ozempic costs sets out the cost picture. The fifth is supervision: whichever you choose, a GPhC-registered prescriber should review you, adjust the dose and check suitability at each repeat.

If you want a prescriber's view on your own situation, you can start your free consultation. It is free, with no obligation, and unsuitable orders are refunded automatically. New customers save £40 on their first order with code FIRST40, and an automatic £25 reorder discount applies to every future order (code DOSE25).

04 · Ozempic's UK licence

Why Ozempic is not a UK weight-loss medicine

Ozempic is semaglutide licensed for type 2 diabetes. It is not a UK weight-loss medicine, and prescribing it privately for weight loss is off-label.¹⁸ For weight loss, the real comparison is Mounjaro with Wegovy, the semaglutide product licensed for weight management.

The licensed weight-management options in the UK are Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg).¹¹⁸ Those are the two medicines with trial programmes designed to measure weight loss and with product information written for it. A regulated UK pharmacy will not supply Ozempic for weight loss. If a seller offers it for that purpose, ask why it is not offering the licensed products, and be cautious about any service that skips a proper consultation or prescription.

Why does the distinction matter beyond paperwork? A licence means a regulator has reviewed the evidence for a specific use, the dose range for that use and the safety information that goes with it. Off-label prescribing can be legitimate in some medical settings, but it is a decision for a prescriber who knows your full history. It is not a shortcut for people who find the licensed route inconvenient. For weight management, both licensed routes are available and the evidence is strong.

The names also cause confusion because Ozempic and Wegovy contain the same active ingredient, semaglutide, made by the same company. They are different products with different licences, different pens and different dose ladders. Wegovy pens run through 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg once weekly, stepping up after at least four weeks and reaching the 2.4mg maintenance dose from week 17. The 2.4mg dose is the licensed maintenance dose for weight management.¹⁸

Mounjaro, by contrast, is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. It is licensed in the UK for weight management in adults and for type 2 diabetes, and comes as a pre-filled multi-dose KwikPen in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ So one medicine carries both licences, and the semaglutide range splits them across two brands.

In practical terms, this means you should compare like with like. If your goal is weight loss, compare Mounjaro with Wegovy. If your goal is blood sugar control in type 2 diabetes, your diabetes team decides between Ozempic and Mounjaro, and our page on whether Mounjaro beats Ozempic for weight loss covers the weight side of that conversation. Whichever route you take, the medicine should come from a registered pharmacy after a prescriber review, not from an unregulated seller.

05 · Ingredients and mechanism

Ingredients in Ozempic vs Mounjaro: how each works

The main ingredient in Ozempic is semaglutide, and the active ingredient in Mounjaro is tirzepatide, so the two do not have the same ingredients. Semaglutide is the same active ingredient used in Wegovy. Tirzepatide is a different molecule with a different action. The leaflets for each product list the full set of non-active ingredients, and the Mounjaro patient information leaflet is the place to check those.¹³

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin.¹ This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy and Ozempic).¹

What does that feel like in practice? Most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹ That is the point of the medicine. It makes a calorie-controlled eating pattern easier to hold, alongside increased physical activity. It does not replace either.

The trial result is what matters for your decision, not the mechanism alone. SURMOUNT-5 measured the outcome directly, and tirzepatide came out ahead.¹⁵

One mechanism detail is worth knowing before you start. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4 to 5 weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹ If you stop treatment or switch, your prescriber will factor that in.

There is also a practical point about the pens. Mounjaro comes as a multi-dose KwikPen, giving four weekly doses per pen at one strength.¹ Wegovy and Ozempic each use their own pens and dose steps, which are not interchangeable with Mounjaro's, and strengths cannot be compared milligram for milligram. A 5mg Mounjaro dose does not equal any particular semaglutide dose, which is why a switch is never done by simple conversion.

For a longer explanation of why the two-receptor design matters, see our guide on what works better for weight loss.

06 · Head-to-head evidence

What SURMOUNT-5 shows about Mounjaro and semaglutide

SURMOUNT-5 is the first large head-to-head trial of tirzepatide against semaglutide 2.4mg (Wegovy) for weight loss. Adults on tirzepatide lost on average 20.2% of body weight over 72 weeks, versus 13.7% on semaglutide 2.4mg.¹⁵ Both are effective, licensed treatments, so a 6.5 percentage point gap in averages should be read as a real difference, not a verdict that Wegovy does not work.

The trial enrolled 751 adults. Average loss was 22.8 kg on tirzepatide against 15.0 kg on semaglutide.¹⁵ As a worked example, for someone starting at 100 kg, 20.2% is about 20 kg and 13.7% is about 14 kg. Your starting weight, dose reached and how closely you follow the diet and activity plan all change your own outcome, and trial averages do not predict your own result.

The threshold figures show where the gap is widest. The share of participants reaching each level of weight loss was:

• At least 10% of body weight: 81.6% on tirzepatide vs 60.5% on semaglutide.
• At least 15%: 64.6% vs 40.1%.
• At least 20%: 48.4% vs 27.3%.
• At least 25%: 31.6% vs 16.1%.

These percentages come from the SURMOUNT-5 results.¹⁵ The gap grows at higher thresholds. That matters if your prescriber's goal is substantial weight loss, for example because of weight-related health conditions. It matters less if a modest, steady reduction would meet your goal and tolerability is your main concern.

Where does Ozempic fit? It does not. SURMOUNT-5 compared tirzepatide with the 2.4mg weight-management dose of semaglutide, which is Wegovy, not Ozempic.¹⁵ That is why we say the useful question is Mounjaro versus Wegovy.

One further caution: SURMOUNT-5 is the first large head-to-head trial, so it is the one that supports a tirzepatide-versus-semaglutide statement. Other trials, such as SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, tested each medicine against placebo or lifestyle changes in different groups of people. Their figures are useful for understanding each medicine on its own, but they should not be set side by side as if they were a contest.

The trial results also assume treatment alongside a reduced-calorie diet and increased physical activity. They are not what a medicine does on its own. Individual results vary, and a prescriber should review your progress and tolerance as you go.¹

07 · Wegovy's own results

How well does semaglutide work on its own terms?

Semaglutide 2.4mg (Wegovy) produces substantial weight loss in its own right. In the STEP 1 trial, adults on semaglutide 2.4mg lost on average 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.⁹ That is a meaningful result, and it is why Wegovy is a licensed UK weight-management medicine. It also explains why choosing Mounjaro is not the same as dismissing semaglutide.

The STEP 1 detail shows how the results were spread. 86.4% of adults on semaglutide 2.4mg lost at least 5% of body weight over 68 weeks, compared with 31.5% on placebo. 69.1% lost at least 10% (vs 12.0% on placebo) and 50.5% lost at least 15% (vs 4.9%).⁹ As a worked example, for someone starting at 100 kg, 14.9% is about 15 kg.

Those numbers are not directly comparable with the tirzepatide figures from SURMOUNT-1, because the trials ran for different lengths with different participants and designs. The fair comparison is SURMOUNT-5. STEP 1 simply tells you what to expect from semaglutide 2.4mg against placebo.

Tolerability is the other half of the picture. In STEP 1, gastrointestinal side effects were reported by 74.2% of people on semaglutide 2.4mg, compared with 47.9% on placebo. 7.0% stopped treatment because of side effects, compared with 3.1% on placebo.⁹ If you are weighing the two medicines, these figures show that side effects are a real consideration with semaglutide at the weight-management dose. Your prescriber and the product leaflets list the side effects for each pen.¹³

What should you do if you are worried about side effects? Tell your prescriber, who can review your dose and plan. You can also report any suspected side effect through the MHRA Yellow Card scheme.¹⁹ Our monthly reviews and side-effect support exist so you are not working through that alone.

Wegovy's dose ladder is gradual by design. Pens run 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg once weekly, with a step up after at least four weeks, reaching the 2.4mg maintenance dose from week 17.¹⁸ Mounjaro also starts low at 2.5mg and steps up through its six strengths. If Wegovy interests you, our Wegovy pen page shows current availability and the first-pen price. If you are undecided, the consultation is a place to talk it through with a prescriber.

08 · Mounjaro dose results

What Mounjaro achieved at each dose in SURMOUNT-1

In SURMOUNT-1, adults taking tirzepatide alongside diet and exercise lost on average 15% of body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² The trial involved 2,539 adults. These are trial averages, individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

The pattern is dose-related. Higher maintenance doses produced higher average loss in the trial. But a higher dose is not automatically better for you. Many people settle at a maintenance dose of 5mg, 10mg or 15mg, and your prescriber will guide the right pace.

The threshold figures give a fuller picture. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.²

As a worked example, for someone starting at 100 kg, 20.9% is about 21 kg and 15% is about 15 kg. Starting weight changes the kilogram figure, but the percentage is the more useful measure for comparing across people.

Higher doses averaged higher loss, but the figures also show something less often said: even the 5mg dose delivered an average 15% loss in SURMOUNT-1.

For another angle on health effects beyond weight, see our page on Ozempic or Mounjaro for inflammation.

09 · NHS and private costs

NHS access and what private Mounjaro costs

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition. The NHS primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting. Your GP can tell you where you stand locally, and the NHS guide to tirzepatide has more information.⁵

Wegovy's NHS access runs through specialist weight-management services; ask your GP.

On the private side, the price depends on the dose. The standard price of one 4-week pen is £169.99 at 2.5mg, £218.99 at 5mg, £279.99 at 7.5mg, £290.99 at 10mg, £319.99 at 12.5mg and £329.99 at 15mg. A new customer gets £40 off their first order at any dose with code FIRST40, including people switching from another provider at a higher dose. Every later order is £25 off the standard price (code DOSE25).

Your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99). Switching at 15mg? Your first order is £289.99. These are first-order prices, not monthly ones.

Planning a whole course helps. If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices. A first year (13 pens) costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg. These totals are before discounts, so a new customer's first order is £40 less and every later order £25 less.

For context on the wider market, across the UK pharmacies we track, Mounjaro pens ranged from £143.96 to £339.00 per month across all doses as of 11 October 2026. The gap between providers for the same dose ran from £27 to £41. Those are index figures for Mounjaro only.

Pharmacy sell prices vary because of confidential discounts, which is why our live prices are shown through the product page. Our guide to whether Mounjaro or Ozempic is cheaper covers cost in more depth.

We are a GPhC-registered UK online pharmacy (9012878), and you can check our entry on the GPhC register.¹² Consultation is free, and the price shown is the price paid.

10 · Switching and safety

Switching from Ozempic or Wegovy, and what not to combine

There is no licensed direct conversion between semaglutide and tirzepatide, so a switch is always prescriber-led. Typically the previous medicine is stopped, a washout interval is observed, and Mounjaro is started at a dose your prescriber judges appropriate. That is often the 2.5mg starting dose, sometimes adjusted based on your history.¹¹ Never run two GLP-1 medicines together.

This matters if you currently take Ozempic for diabetes and are wondering whether Mounjaro would suit you better. Do not stop or change a diabetes medicine on your own. Speak to the clinician who manages your diabetes first. Where a person also uses insulin or a sulfonylurea, doses may need adjusting because of the risk of low blood sugar, and that is a conversation for the prescriber.

Mounjaro must also not be combined with other GLP-1 medicines, unlicensed "research" peptides (such as retatrutide, which has no UK licence) or compounded copies. These combinations have no safety data and no regulated supply chain.⁷ If something promises faster results outside a licensed pathway, that is the warning sign. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme, and we recommend reporting anything suspicious.⁷

Contraception is another point to raise. Mounjaro slows stomach emptying, which can reduce how well oral contraceptive pills are absorbed.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹

What about tablets and "cheaper alternatives"? There is no tablet form of Mounjaro, because tirzepatide is injection-only in the UK. Two GLP-1 weight-loss tablets are now licensed: Wegovy tablets (oral semaglutide, made by Novo Nordisk), approved by the MHRA in June 2026, and Foundayo (orforglipron, made by Eli Lilly), approved in August 2026.²⁰²¹ They are different medicines from Mounjaro, with their own dosing, eligibility checks and trial results, and both are prescription-only. See current Wegovy tablet prices on the weight loss treatments hub.

Other licensed options work differently. Orlistat (tablet) blocks some dietary fat absorption and produces smaller average losses. Wegovy and Saxenda (liraglutide) are other licensed injectables, and liraglutide is a daily injection, unlike once-weekly Mounjaro and Wegovy. "Natural GLP-1" supplements such as berberine are not medicines, are not regulated for this use and have no comparable trial evidence. They are low-cost supplements with no clinical oversight, and dosing is not standardised.

Pick one licensed medicine, take it under a prescriber's review and never layer treatments to chase speed.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

12 · Ordering with us

How to order Mounjaro from EverydayMeds

Ordering Mounjaro with us takes four steps, and the first is a free online consultation. It is a short health questionnaire with no charge and no obligation. A GPhC-registered prescriber then reviews it, not a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

Once approved, the pen is dispensed by our registered pharmacy. We dispatch the same day when you order by 3pm. Delivery is free, next day and tracked through DPD in temperature-controlled, discreet packaging. Saturday delivery is £14.99. Needles, a sharps bin and injection guidance are included with every order. We supply through official LillyDirect, direct from Eli Lilly's UK distribution, so the KwikPens are genuine, and all six doses are in stock.

What happens after the first pen? Ongoing monthly reviews, dose-titration and follow-up assessments are carried out by the prescribing team, with side-effect support. Repeat orders re-check suitability, and there is no auto-shipping and no subscription lock-in. You can pay by Visa or Mastercard, Klarna or pay-monthly options.

A few points specific to this comparison. First, if you have been taking Ozempic for diabetes, tell the prescriber in the consultation, because it changes the plan. Second, if you are on Wegovy and want to move, say what dose you reached and how you tolerated it, because that guides the starting dose and washout. Third, do not start a Mounjaro pen while still using another GLP-1 medicine.

Is there support if something goes wrong? Our team is available Monday to Friday, 9am to 5pm, at support@everydaymeds.co.uk, through the account portal chat or by phone on 0333 207 0413. Declined consultations are refunded automatically in full. Dispensed prescription medicines cannot be returned unless faulty, damaged or the wrong item, in which case contact us within 3 days. Refunds take 5 to 10 working days.

You can also use GLPTrackr, our free companion app for iOS and Android, to track your journey.

Mounjaro (tirzepatide) is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Individual results vary. This page is information, not a substitute for medical advice. To see where you stand, begin the free consultation or view the Mounjaro pen prices and consultation.